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ABSTRACT
Macrophage activation syndrome (MAS) is a rare life-threatening complication
that can occur in patients with systemic lupus erythematosus (SLE) and other
connective tissue diseases. It is universally fatal without treatment and therefore
prompt diagnosis and initiation of treatment are of vital importance.
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INTRODUCTION
Our case report highlights the rare occurrence of MAS
as a complication of SLE in a young adult male and
the importance of timely diagnosis and treatment to
reduce morbidity and mortality.
CASE PRESENTATION
A 31-year old male with no significant past
medical history presented with a 2-day history of
progressively worsening bilateral lower extremity
edema and facial puffiness. Associated symptoms
were fatigue, chills, myalgia, and arthralgia of
both hands and feet. Initial workup revealed acute
kidney injury in the setting of nephrotic syndrome.
Autoimmune workup revealed elevated titers of
antinuclear antibodies (ANA) (1:640), positive antiSmith antibody titer (467 units/ml), low complement
levels (C3 – 46 mg/dl and C4 – 3.4 mg/dl) with
negative titers of anti-double-stranded DNA(dsDNA)
antibodies, cytoplasmic antinuclear cytoplasmic
antibodies (c-ANCA) and perinuclear antinuclear
cytoplasmic antibodies (p-ANCA). The infectious
workup was negative. Renal biopsy was consistent
with class V lupus nephritis. Subsequently, the
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rheumatology team was consulted and the patient
was started on 60 mg IV methylprednisolone daily
and 500 mg oral mycophenolate mofetil twice
daily. Over the next 1-2 days, with IV steroids
and IV diuresis, the patient clinically improved.
Subsequently, IV methylprednisolone was tapered
and switched to oral prednisone. However,
the patient deteriorated again and developed
persistent high-grade fever with chills. Lab work
(see investigations below) revealed an acute drop in
cell counts, worsening liver function, and elevated
inflammatory markers.
Hemoglobin – 8.1 mg/dl (was 12.5 mg/dL 24 hours
prior)
White blood cell (WBC count) – 3.66 k/mcl (was 9.09
k/mcl 24 hours prior)
Platelet count – 70 k/mcl (was 167 k/mcl 24 hours
prior)
Alanine transaminase (ALT) – 93 U/L (was 29 U/L 24
hours prior)
Aspartate transaminase (AST)- 239 U/L (was 38 U/L 24
hours prior)
Alkaline phosphatase – 95 U/L (was 62 U/L 24 hours
prior)
Total Bilirubin – 2.0 mg/dl (was 0.2 mg/dL 24 hours
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prior)
C-reactive protein (CRP) – 40.8 mg/dl (was 7.3 mg/dL
48 hours prior)
Erythrocyte sedimentation rate (ESR) - > 140 mm/hr
C3 – 110 mg/dL
C4 – 5.8 mg/dL
Sepsis was ruled out after an extensive infectious
workup including blood cultures, CT imaging of
chest/abdomen/pelvis and transthoracic echo
revealed no evidence of infection. Lupus flare was
considered to be less likely due to elevated C3 and
C4 levels. Further workup revealed an elevated serum
ferritin level at 303,520 ng/ml. Fibrinogen level was
elevated at 451 mg/dl. Triglyceride level was elevated
at 872 mg/dl. Based on pancytopenia, transaminitis,
hypertriglyceridemia, and hyperferritinemia, MAS
was strongly suspected. Subsequently, a bone
marrow biopsy was done which was consistent
with MAS showing histiocytes with phagocytized
hematopoietic cells and debris (Figure 1).
Immunohistochemistry and phenotyping of the bone
marrow specimen did not reveal any evidence of
leukemia or lymphoma.
Subsequently, the patient was started on IV pulse
methylprednisolone 1000 mg daily for 3 days
following which there was a significant improvement
both clinically as well as with laboratory function
tests. The patient was started on anakinra 100 mg
subcutaneously and IV methylprednisolone 60 mg

twice daily for treatment of the MAS. Unfortunately,
after 3 days of treatment with anakinra, the patient
developed fevers with acute respiratory distress.
Chest X-ray showed a new lung infiltrate and sputum
cultures revealed Klebsiella pneumonia. Anakinra
was discontinued and IV methylprednisolone
was continued. With IV antibiotics the patient’s
pneumonia improved. He was continued on IV
methylprednisolone taper. After a prolonged and
complicated hospital course lasting 3 months, he
was finally discharged to a rehabilitation facility.
He was discharged on hydroxychloroquine 400 mg
daily and IV methylprednisolone 15 mg twice daily.
During his rehabilitation stay, he was transitioned
to oral prednisone taper. Over the next few months,
he continued to improve clinically and regained
his physical strength and was able to function
independently. He was started on 500 mg oral
mycophenolate mofetil twice daily and is currently
doing well on this as well as 2.5 mg oral prednisone
daily and hydroxychloroquine 400 mg daily.
DISCUSSION
Macrophage activation syndrome (MAS) is a
life-threatening complication that is classified
among the group of histiocytic disorders called
hemophagocytic lymphohistiocytosis (HLH).1,2
The incidence of MAS in autoimmune rheumatic
disorders is 4.2% and the mortality is 40%.3 MAS

FIGURE 1. Bone marrow biopsy showing multinucleated histiocytes (shown by arrows) with phagocytosed
hematopoietic cells and debris consistent with the diagnosis of macrophage activation syndrome.
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was first described in a case of systemic-onset
juvenile rheumatoid arthritis by Hadchouel et al.4 It is
commonly seen as a complication of systemic-onset
juvenile idiopathic arthritis (SJIA), Kawasaki disease,
SLE, adult-onset Still’s disease (AOSD), rheumatoid
arthritis (RA), ankylosing spondylosis (AS), sarcoidosis
and dermatomyositis.5 The prevalence of MAS
among SLE patients ranges from 0.9% - 4.6%.2,6
The exact pathogenesis of MAS is not fully
understood but is hypothesized to involve
uncontrolled activation and proliferation of
natural killer (NK) and cytotoxic T cells within the
reticuloendothelial system resulting in a hyperinflammatory state.7 This immune dysregulation
results in a surge of macrophage colony-stimulating
factor (M-CSF) and Th1 cytokines (interferon-y,
interferon-a, interleukin-1, interleukin-6), promoting
inappropriate activation of macrophages resulting in
various clinical features of MAS.8
The clinical symptoms and signs of MAS
may include persistent fever, splenomegaly,
hepatomegaly, renal involvement, mental status
changes, and hemorrhagic manifestations.9
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cytopenia or pancytopenia,
hypofibrinogenemia,
hypertriglyceridemia,
hyperferritinemia, and
transaminitis. Numerous
macrophages containing
phagocytized cell elements
(typically leukocytes or
erythrocytes) can be seen
on bone marrow biopsy.10, 11
A key pathologic finding of
HLH related disorders is the
presence of hemophagocytes
in the bone marrow, spleen
or lymph nodes. However, the
presence of hemophagocytes is
not considered a pathognomic
feature as it has a sensitivity
up to 83% but a specificity of
only 60%.12 It should be noted
that hyperferritinemia is the
best indicator to distinguish
MAS complicating SLE from SLE
flare, with a high sensitivity and

Modified HLH 2004 diagnostic criteria (Table 1),
proposed by Henter et al, is a widely accepted guide
used to diagnose MAS complicating SLE.14
According to the 2004 HLH criteria, MAS diagnosis is
made when either molecular testing is done for gene
mutation or when 5 out of 8 diagnostic criteria are
met. The initial treatment of MAS includes control of
the hyperinflammatory state with intravenous high
dose pulse methylprednisolone, identification, and
treatment of the underlying trigger as well as the
use of biologic drugs such as infliximab, etanercept
or rituximab (anti-CD20 monoclonal antibody).10
Anakinra, which is an interleukin-1 (IL-1) inhibitor,
has become a more favored treatment option
regardless of underlying autoimmune disorder.15, 16
Hematopoietic stem cell transplant (HCT) is the gold
standard of treatment in genetic cases and familial
HLH as it is the only curative option with survival
rates of 50-70% at 5 years.17
In conclusion, MAS is a rare but fatal complication
that can occur among autoimmune rheumatic
disorders. Physicians should have a high degree
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of suspicion for diagnosing MAS in the setting of
appropriate clinical symptoms and signs. Timely
initiation of treatment is critical to prevent the high
mortality rate.
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